Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Long-Term Investments (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Long-Term Investments for 14 consecutive years, with $22.5 million as the latest value for Q1 2026.

  • Quarterly Long-Term Investments rose 20.62% to $22.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22.5 million through Jan 2026, up 20.62% year-over-year, with the annual reading at $22.5 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments for Q1 2026 was $22.5 million at PharmaCyte Biotech, up from $20.7 million in the prior quarter.
  • The five-year high for Long-Term Investments was $29.1 million in Q3 2024, with the low at $1.6 million in Q1 2022.
  • Average Long-Term Investments over 5 years is $10.8 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Long-Term Investments skyrocketed 1752.19% in 2024, then plummeted 32.57% in 2025.
  • Over 5 years, Long-Term Investments stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then soared by 1480.91% to $24.9 million in 2024, then decreased by 16.53% to $20.7 million in 2025, then increased by 8.31% to $22.5 million in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $22.5 million, $20.7 million, and $19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.